INVESTIGADORES
TOMAT Analia Lorena
artículos
Título:
Changes in bone volume and bone resorption after olpadronate treatment in an experimental model of uremic bone disease
Autor/es:
TOMAT AL; GAMBA C A; MANDALUNIS P; DE GRANDI MC; SOMOZA J; FRIEDMAN S; ZENI S
Revista:
Journal of Musculoskeletal & Neuronal Interactions
Editorial:
Hylonome
Referencias:
Lugar: Grecia; Año: 2005 vol. 5 p. 174 - 181
ISSN:
1108-7161
Resumen:
Abstract
Thirty male adult Wistar rats (300±10 g body weight) underwent either 5/6 nephrectomy (Nx, n=20) or sham operation
(SHAM, n=10) to determine olpadronate effects in an experimental model of uremic bone disease. For a 38-day period, 10
rats received olpadronate (16ug/100g bw) once a week (Nx+OPD) and the other vehicle (Nx). SHAM received vehicle. At
baseline, treatment onset (t=7days) and end of study (t=45 days) calcium, phosphorus, creatinine, bone alkaline phosphatase
(b-ALP) and deoxypyridinoline crosslinks (DPyr) were determined. At t=0 and t=45 bone mineral density (BMD) was measured
by DXA. At t=45 the right tibia was removed for bone histology. There were no differences in serum calcium.
Phosphorus increased in Nx and Nx+OPD compared to SHAM (p<lt 0.05). The b-ALP increased from t=0 to t=7 in Nx and
Nx+OPD (p<0.05) and decreased thereafter to SHAM levels. DPyr/creat increased in Nx compared to SHAM (p<0.05) and
Nx+OPD (p< 0.001). Nx+OPD presented lower DPyr excretion than SHAM rats (p<0.01). At t=45, tibia BMD of Nx was
20% and 26% lower than in SHAM (p<0.005) and Nx+OPD, respectively, (p<0.001). BMD was higher Nx+OPD than in
SHAM (p<0.05). OPD prevented the loss of bone volume, the increment in osteoid volume and erosion surface observed in
Nx group (p<0.05). OPD also prevent the increment in the number of osteoclasts (OC) and the active OC surface and
decreases the number of TRAP(+)-OC (p<0.05). In summary, OLP may be beneficial in osteopenia associated to high
turnover bone disease of CRF. However, the use of bisphosphonate therapy for renal insufficiency must be further investigated
in order to clarify essential aspects of treatment as the patient selection and several aspects of treatment, such as optimum
dose, frequency, and safe period of administration.
Keywords: Uremic Bone Disease, Olpadronate, High Turnover, DXA, RatsUremic Bone Disease, Olpadronate, High Turnover, DXA, Rats